Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | CTSG | P08311 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12205992 | 0.81 | ALDH1A1 (0.58) | KMT2AMEN1GAAHTTMAPT | |
| SCHEMBL17358741 | 0.81 | ELANE (0.67) | KMT2AMEN1MAPTUSP2GSK3A | |
| SCHEMBL10159046 | 0.75 | ELANE (0.62) | KMT2AMEN1GAAHTTMAPT | |
| SCHEMBL18181914 | 0.75 | GAA (0.64) | KMT2AMEN1GAAHTTMAPT | |
| SCHEMBL10158776 | 0.74 | KMT2A (1.00) | KMT2AMEN1GAAHTTMAPT | |
| SCHEMBL20673341 | 0.73 | F2 (0.64) | KMT2AMEN1GAAHTTMAPT | |
| SCHEMBL11704244 | 0.71 | EHMT2 (0.53) | KMT2AMEN1GAAHTTMAPT | |
| SCHEMBL28234264 | 0.71 | GSK3A (1.00) | KMT2AMEN1GAAHTTMAPT | |
| SCHEMBL211905 | 0.71 | GSK3A (1.00) | KMT2AMEN1GAAHTTMAPT | |
| SCHEMBL15131562 | 0.70 | EP300 (0.55) | KMT2AMEN1GAAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3144299-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Cambria Pharmaceuticals, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9499494-B2 | Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499494-B2 | Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2427438-B1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20150203456-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2015-07-23 | — | — | US | disclosed |
| US-20150203456-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2015-07-23 | — | — | US | disclosed |
| US-20120046309-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NORTHWESTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046309-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NORTHWESTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010129665-A2 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203456-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NUDT1, TYMP, HPRT1 | KMT2A 946/4885MEN1 4617/4885GAA 1079/4885 |
| US-20120046309-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NUDT1, TYMP, HPRT1 | KMT2A 946/4885MEN1 4617/4885GAA 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.